Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer’s disease

Kelly Ceyzériat(Université Paris-Sud), Lucile Ben Haim(Université Paris-Sud), Audrey Denizot(Université de Bordeaux), Dylan Pommier(Université de Bordeaux), Marco Matos(Université de Bordeaux), Océane Guillemaud(Université Paris-Sud), Marie-Ange Palomares(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Laurene Abjean(Université Paris-Sud), Fanny Petit(Université Paris-Sud), Pauline Gipchtein(Université Paris-Sud), Marie‐Claude Gaillard(Université Paris-Sud), Martine Guillermier(Université Paris-Sud), Suéva Bernier(Université Paris-Sud), Mylène Gaudin(Université Paris-Sud), Gwenaëlle Aurégan(Université Paris-Sud), Charlène Joséphine(Université Paris-Sud), Nathalie Déchamps(Université Paris-Sud), Julien Veran(Université de Bordeaux), Valentin Langlais(Université de Bordeaux), Karine Cambon(Université Paris-Sud), Alexis‐Pierre Bemelmans(Université Paris-Sud), Jan Baijer(Université Paris-Sud), Gilles Bonvento(Université Paris-Sud), Marc Dhénain(Université Paris-Sud), Jean‐François Deleuze(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Stéphane H. R. Oliet(Université de Bordeaux), Emmanuel Brouillet(Université Paris-Sud), Philippe Hantraye(Université Paris-Sud), María-Angeles Carrillo-de Sauvage(Université Paris-Sud), Robert Olaso(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Aude Panatier(Université de Bordeaux), Carole Escartin(Université Paris-Sud)
Acta Neuropathologica Communications
October 15, 2018
Cited by 273Open Access
Full Text

Abstract

Astrocyte reactivity and neuroinflammation are hallmarks of CNS pathological conditions such as Alzheimer's disease. However, the specific role of reactive astrocytes is still debated. This controversy may stem from the fact that most strategies used to modulate astrocyte reactivity and explore its contribution to disease outcomes have only limited specificity. Moreover, reactive astrocytes are now emerging as heterogeneous cells and all types of astrocyte reactivity may not be controlled efficiently by such strategies.Here, we used cell type-specific approaches in vivo and identified the JAK2-STAT3 pathway, as necessary and sufficient for the induction and maintenance of astrocyte reactivity. Modulation of this cascade by viral gene transfer in mouse astrocytes efficiently controlled several morphological and molecular features of reactivity. Inhibition of this pathway in mouse models of Alzheimer's disease improved three key pathological hallmarks by reducing amyloid deposition, improving spatial learning and restoring synaptic deficits.In conclusion, the JAK2-STAT3 cascade operates as a master regulator of astrocyte reactivity in vivo. Its inhibition offers new therapeutic opportunities for Alzheimer's disease.


Related Papers

No related papers found

Powered by citation graph analysis